Clinical Trial Update: HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for HX575 epoetin alfa given subcutaneously in chronic kidney disease; the study has completed and results were posted in June 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• HX575 epoetin alfa (epoetin alfa)

Snippet

Sponsor: Sandoz | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-06-19